257 related articles for article (PubMed ID: 21658040)
1. The hemostatic efficacy of platelet components prepared with pathogen inactivation.
Corash L
Transfusion; 2011 Jun; 51(6):1355-6; author reply 1356-7. PubMed ID: 21658040
[No Abstract] [Full Text] [Related]
2. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets.
Vamvakas EC
Transfusion; 2011 May; 51(5):1058-71. PubMed ID: 21058955
[TBL] [Abstract][Full Text] [Related]
3. Automated preparation of platelet concentrates from pooled buffy coats using the Gambro OrbiSac system.
Gulliksson H; Sjödin A; Sandgren P; Vesterinen M; Larsson S; Diedrich B
Transfus Apher Sci; 2003 Aug; 29(1):11-2. PubMed ID: 12877886
[No Abstract] [Full Text] [Related]
4. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Windeløv NA; Salado-Jimena JA; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2011 Feb; 51(2):344-56. PubMed ID: 20723169
[TBL] [Abstract][Full Text] [Related]
5. Platelets stored in whole blood at 4°C: in vivo posttransfusion platelet recoveries and survivals and in vitro hemostatic function.
Slichter SJ; Fitzpatrick L; Osborne B; Christoffel T; Gettinger I; Pellham E; Bailey SL; Jones MK; Herzig MC; Cap AP
Transfusion; 2019 Jun; 59(6):2084-2092. PubMed ID: 30977914
[TBL] [Abstract][Full Text] [Related]
6. Preparation, storage and quality control of platelet concentrates.
Tynngård N
Transfus Apher Sci; 2009 Oct; 41(2):97-104. PubMed ID: 19699153
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma.
Vassallo RR; Adamson JW; Gottschall JL; Snyder EL; Lee W; Houghton J; Elfath MD
Transfusion; 2010 Nov; 50(11):2376-85. PubMed ID: 20497516
[TBL] [Abstract][Full Text] [Related]
8. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
[TBL] [Abstract][Full Text] [Related]
9. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial.
Pineda A; McCullough J; Benjamin RJ; Cable R; Strauss RG; Burgstaler E; Porter S; Lin L; Metzel P; Conlan MG;
Transfusion; 2006 Apr; 46(4):562-71. PubMed ID: 16584432
[TBL] [Abstract][Full Text] [Related]
10. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
11. Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply.
Zimmermann R; Blasczyk R; Zingsem J; Eckstein R; Heuft HG
Vox Sang; 2010 Oct; 99(3):295-6; author reply 297-8. PubMed ID: 20561324
[No Abstract] [Full Text] [Related]
12. The ethics of wasting the donor's gift of buffy coat.
Vamvakas EC
Vox Sang; 2011 Feb; 100(2):256-7; author reply 258-9. PubMed ID: 20825600
[No Abstract] [Full Text] [Related]
13. Evaluation of platelet transfusion clinical trials.
Corash L; Sherman CD
Br J Haematol; 2011 May; 153(4):529-31; author reply 531-2. PubMed ID: 21275946
[No Abstract] [Full Text] [Related]
14. Treating thrombocytopenia with pathogen-reduced platelets.
Sandler SG
Curr Hematol Rep; 2006 Mar; 5(1):53-4. PubMed ID: 16537046
[No Abstract] [Full Text] [Related]
15. [Effect of preparation and preservation modality on thrombocyte quality].
Mohren M; Müller H; Körner K; Wiesneth M; Kubanek B; Heimpel H; Seifried E
Beitr Infusionsther; 1993; 31():107-10. PubMed ID: 7693237
[TBL] [Abstract][Full Text] [Related]
16. High concentration plasma-reduced plateletapheresis concentrates.
Perseghin P
Transfus Apher Sci; 2011 Jun; 44(3):273-6. PubMed ID: 21507725
[TBL] [Abstract][Full Text] [Related]
17. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal.
Veeraputhiran M; Ware J; Dent J; Bornhorst J; Post G; Cottler-Fox M; Pesek G; Theus J; Nakagawa M
Transfusion; 2011 May; 51(5):1030-6. PubMed ID: 20946201
[TBL] [Abstract][Full Text] [Related]
18. [The quality of platelet concentrates in dependence on storage time before pathogen inactivation].
Bujno M; Lipska A; Zebrowska A; Wróbel J; Gawrylak-Dryja E; Nedzi M; Radziwon P
Pol Merkur Lekarski; 2011 Mar; 30(177):187-90. PubMed ID: 21544995
[TBL] [Abstract][Full Text] [Related]
19. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
Lozano M; Cid J
Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials.
Cid J; Escolar G; Lozano M
Vox Sang; 2012 Nov; 103(4):322-30. PubMed ID: 22563850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
